{"id":"NCT02195700","sponsor":"Auspex Pharmaceuticals, Inc.","briefTitle":"Aim to Reduce Movements in Tardive Dyskinesia","officialTitle":"A Randomized, Double-Blind, Placebo-Controlled Study of SD-809 (Deutetrabenazine) for the Treatment of Moderate to Severe Tardive Dyskinesia","status":"COMPLETED","phase":"PHASE2","dates":{"start":"2014-06","primaryCompletion":"2015-05","completion":"2015-05","firstPosted":"2014-07-21","resultsPosted":"2018-03-20","lastUpdate":"2021-11-09"},"enrollment":117,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"TREATMENT"},"conditions":["Tardive Dyskinesia"],"interventions":[{"type":"DRUG","name":"SD-809","otherNames":["deutetrabenazine","AUSTEDOÂ®"]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"SD-809","type":"EXPERIMENTAL"},{"label":"Sugar Pill","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of this study is to determine whether an investigational drug, SD-809 (deutetrabenazine), will reduce the severity of abnormal involuntary movements of tardive dyskinesia.","primaryOutcome":{"measure":"Change in Centrally Read Abnormal Involuntary Movement Scale (AIMS) Score From Baseline to Week 12 Using Mixed Model Repeated Measures (MMRM) Analysis","timeFrame":"Day 0 (Baseline), Weeks 2, 4, 6, 9 and 12","effectByArm":[{"arm":"SD-809","deltaMin":-3,"sd":0.45},{"arm":"Placebo","deltaMin":-1.6,"sd":0.46}],"pValues":[{"comp":"OG000 vs OG001","p":"0.0188"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":8,"exclusionCount":11},"locations":{"siteCount":41,"countries":["United States","Czechia","Poland","Slovakia"]},"refs":{"pmids":["38557959"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":3,"n":58},"commonTop":["Somnolence","Fatigue","Headache","Dry mouth","Diarrhoea"]}}